Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) on Friday, plunged -4.25% from the previous trading day, before settling in for the closing price of $44.48. Within the past 52 weeks, RARE’s price has moved between $37.02 and $60.37.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 62.14%. The company achieved an average annual earnings per share of 16.82%. With a float of $86.48 million, this company’s outstanding shares have now reached $92.50 million.
Let’s determine the extent of company efficiency that accounts for 1294 employees. In terms of profitability, gross margin is 82.86%, operating margin of -102.49%, and the pretax margin is -107.33%.
Ultragenyx Pharmaceutical Inc (RARE) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ultragenyx Pharmaceutical Inc is 6.51%, while institutional ownership is 95.63%. The most recent insider transaction that took place on Dec 30 ’24, was worth 495,231. In this transaction President & CEO of this company sold 11,727 shares at a rate of $42.23, taking the stock ownership to the 2,183,985 shares. Before that another transaction happened on Dec 30 ’24, when Company’s Officer proposed sale 11,727 for $42.23, making the entire transaction worth $495,264.
Ultragenyx Pharmaceutical Inc (RARE) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.35 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 16.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 82.20% during the next five years compared to 2.45% growth over the previous five years of trading.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Trading Performance Indicators
Ultragenyx Pharmaceutical Inc (RARE) is currently performing well based on its current performance indicators. A quick ratio of 2.65 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.03.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.34, a number that is poised to hit -1.56 in the next quarter and is forecasted to reach -3.63 in one year’s time.
Technical Analysis of Ultragenyx Pharmaceutical Inc (RARE)
Looking closely at Ultragenyx Pharmaceutical Inc (NASDAQ: RARE), its last 5-days average volume was 0.79 million, which is a drop from its year-to-date volume of 0.88 million. As of the previous 9 days, the stock’s Stochastic %D was 44.39%. Additionally, its Average True Range was 1.78.
During the past 100 days, Ultragenyx Pharmaceutical Inc’s (RARE) raw stochastic average was set at 15.38%, which indicates a significant decrease from 18.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.64% in the past 14 days, which was lower than the 36.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $43.71, while its 200-day Moving Average is $47.25. However, in the short run, Ultragenyx Pharmaceutical Inc’s stock first resistance to watch stands at $44.21. Second resistance stands at $45.84. The third major resistance level sits at $46.67. If the price goes on to break the first support level at $41.75, it is likely to go to the next support level at $40.92. Now, if the price goes above the second support level, the third support stands at $39.29.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Key Stats
Market capitalization of the company is 3.94 billion based on 92,501K outstanding shares. Right now, sales total 560,230 K and income totals -569,180 K. The company made 164,880 K in profit during its latest quarter, and -133,390 K in sales during its previous quarter.
